CS
PHAS

Candriam SCA’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Candriam SCA’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,081,258
Closed -$3.36M – 884
2021
Q3 		$3.36M Buy
1,081,258
+461,824
+75% +$1.54M 0.02% 473
2021
Q2 		$2.3M Buy
+619,434
New +$2.06M 0.02% 560
2019
Q4 		– Sell
-105,423
Closed -$440K – 811
2019
Q3 		$440K Buy
+105,423
New +$841K 0.01% 694

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Candriam SCA's PHAS Position: Q4 2021 in Review

Candriam SCA sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2021, closing a stake of 1,081,258 shares — an estimated $3.36M sold.

Candriam SCA first reported a position in PHAS in Q3 2019 and held it in 3 quarters. The position peaked at $3.36M in Q3 2021. 51 funds tracked by Wall St. Rank hold PHAS as of Q4 2021.

  • Candriam SCA reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Candriam SCA sold 1,081,258 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $3.36M.
  • Candriam SCA first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 3 quarters.
  • Candriam SCA's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $3.36M in Q3 2021.
  • 51 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.